Research and development expenses were $3.3m, compared to $1.1m for the same period in 2010, primarily related to the advancement of the Phase III clinical development program for lead compound, lomitapide.
Aegerion Pharma CEO Marc Beer said they are pleased to report that they remain on track with all clinical and regulatory objectives, and their corporate goal of submitting both NDA and MAA filings by year-end.
"We are building a management team, with collective global experience in drug development, finance and operations, and commercialization," Beer said.
We are managing our filing process and planning carefully, and I have great confidence in our ability to gain approval in the US and Europe in 2012."